# Clinical complete response achieved in patients with breast cancer liver metastasis after personalized treatment: a case report and literature review

## TL;DR

A breast cancer patient with liver metastasis achieved full recovery after personalized treatment based on organoid drug testing.

## Contribution

This is the first reported case of clinical complete response in breast cancer liver metastasis using patient-derived organoid drug sensitivity testing.

## Key findings

- A breast cancer patient with liver metastasis achieved clinical complete response after treatment with eribulin and capecitabine.
- Patient-derived organoids predicted drug sensitivity and guided treatment selection in this case.
- The findings support the use of organoids to improve outcomes in advanced or refractory breast cancer.

## Abstract

Patient-derived organoids (PDOs) have been demonstrated not only to predict the response to neoadjuvant chemotherapy but also to tailor the treatment options for advanced breast cancer to improve prognosis. Here, we first reported a case of breast cancer liver metastasis that obtained clinical complete response (cCR) after treatment with eribulin and capecitabine, which showed sensitivity in the organoid drug sensitivity testing, and we conducted a systematic literature review. Our case report further provides a scientific basis for the PDOs as a powerful preclinical model to predict individual treatment sensitivity and improve the treatment outcomes of patients with advanced breast cancer, especially those with refractory or heavily treated breast cancer.